The FDA held a Summit to survival bar in its review of ivonescimab, with the agency citing issues for the approval path in a CRL context. BIOCENTURY reports that additional follow-up helped clarify activity in Western patients, but the primary analysis did not meet expectations in EGFR-mutant non-small cell lung cancer. This kind of regulatory step indicates the agency is pressuring sponsors to resolve efficacy uncertainties and ensure statistical rigor and clinically meaningful benefit, particularly by biomarker-defined subpopulations. For oncology developers, the signal is clear: trial narratives often hinge on whether the primary endpoint analysis and subgroup performance align with regulatory thresholds. The decision will likely affect timelines for next regulatory interactions and could force changes to post-CRL plans, including additional analyses, endpoint recalibration, or new study designs. Industry stakeholders will focus on what the sponsor needs to demonstrate next—durability, magnitude of survival benefit, and whether the evidence package can credibly support labeling in a defined molecular segment.